Leo Pharma
Leo Pharma, officially known as Leo Pharmaceutical Products Ltd., is a global leader in dermatology and critical care, headquartered in Denmark (DK). Founded in 1908, the company has established a strong presence in Europe, North America, and Asia, focusing on innovative solutions for skin diseases and conditions. With a commitment to research and development, Leo Pharma offers a range of unique products, including topical treatments and biologics, specifically designed for conditions such as psoriasis and eczema. The company is renowned for its patient-centric approach, ensuring that its therapies are both effective and accessible. As a prominent player in the pharmaceutical industry, Leo Pharma has achieved significant milestones, including numerous partnerships and advancements in dermatological care, solidifying its position as a trusted name in the market.
DitchCarbon Score
How does Leo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Leo Pharma's score of 49 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Leo Pharma's reported carbon emissions
In 2023, LEO Pharma reported total greenhouse gas emissions of approximately 22851000 kg CO2e for Scope 1, 704000 kg CO2e for Scope 2, and 288558000 kg CO2e for Scope 3. This reflects a commitment to reducing absolute Scope 1 and 2 emissions by 53% by 2030, using 2019 as the baseline year. Additionally, LEO Pharma aims for 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2026. Over the years, LEO Pharma's emissions have varied, with Scope 1 emissions peaking at approximately 24471000 kg CO2e in 2020. The company has made significant strides in addressing its carbon footprint, aligning its targets with the 1.5°C climate goal. The commitment to these reductions underscores LEO Pharma's proactive approach to sustainability and climate responsibility within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2010 | 2011 | 2012 | 2013 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 12,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,100 | 00,000 | 00,000 | 00,000 | 00,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 388,000 | 000,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Leo Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
